Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss itch is caused by DHT attacking follicles and stimulating nerves. Finasteride users who respond well don't experience this itch.

New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.

The conversation discusses experiences with PTD-DBM for hair loss treatment. It also mentions using Minoxidil, finasteride, and RU58841.

A user experienced increased hair density loss after 4 months on dutasteride combined with finasteride. They are also using topical dutasteride with azelaic acid and alfatradiol but cannot tolerate antiandrogens like RU58841 due to headaches.

Hair loss discussion includes DIY HMI-115 and its high cost (20-30k per person). Minoxidil, finasteride, and RU58841 mentioned as treatments.

The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.

The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.

The user experimented with finasteride to reduce hair loss and plans to test if creatine affects DHT levels while on finasteride. Initial results showed low DHT levels, indicating finasteride's effectiveness, with further tests planned for creatine's impact.

The user has been using finasteride for over two years with mixed results and is considering starting dutasteride and oral minoxidil, though both are hard to obtain. They are also contemplating a hair transplant in the future due to diffuse thinning.

The user is experimenting with GHK-Cu and AHK-Cu to stop hair loss and promote hair growth, using a serum from Etsy and injectable GHK-Cu. They supplement this with dermastamping and ketoconazole shampoo.

The user experienced severe scalp itching and hair loss while on dutasteride, which they linked to caffeine and masturbation. They plan to cut out both to see if their hair density improves.

A woman experiencing hormonal hair loss is on dutasteride and bicalutamide, which initially improved her hair, but she is now experiencing a second shedding phase with significant short hair loss. Despite normal hormone levels and no deficiencies, she is unsure if this shedding is normal and seeks advice.

A user reported losing 150-250 hairs daily after 9 months on dutasteride, despite previously stabilizing hair loss with finasteride and minoxidil. Blood tests showed high DHT levels, and the user is unsure if they should continue the current treatment.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

The user is taking 2.5 mg dutasteride and 5% minoxidil but is not seeing hair regrowth, and is considering adding RU58841. They are experiencing fatigue and low MCV/MCH, possibly related to dutasteride, and are advised to be patient, consider microneedling, and check for iron deficiency.

A 35-year-old shared their 1-year hair loss treatment progress using 0.5mg Dutasteride, 5mg oral Minoxidil, topical Minoxidil, and Ducray Anaphase+ shampoo daily, noting significant changes after 4 months despite some shedding. They reported minor side effects and followed their dermatologist's advice for the treatment plan.

The conversation discusses the use of dutasteride and finasteride for hair loss, including switching between them, optimal dosing, and managing side effects. The user has transcriptions of videos on these topics and offers them to others interested.

HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.

The conversation discusses the potential benefits of creating a hydrophobic version of finasteride to reduce systemic side effects while maintaining scalp health. It compares this idea to fluridil, which is designed to be hydrophobic and has less systemic absorption.

HMI-115, a potential treatment for hair loss that has been reported to produce significant regrowth in bald areas. It is the closest thing to a cure currently available and has raised hope that it could make hair transplants obsolete.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

The user experienced persistent acne and skin issues with dutasteride, leading them to stop its use. They switched to finasteride, which caused mild acne and potential liver concerns, prompting consideration of alternative treatments like topical finasteride and GHK-Cu.

A Dutasteride Simulator predicts serum dutasteride, serum DHT, and scalp DHT levels using models from research papers. It simulates various dosing schedules to determine steady-state effects and visualizes outcomes, including hair growth-related scalp DHT suppression.

The user experienced significant hair improvement after 15 months of treatment, using finasteride initially, then switching to dutasteride, and recently adding topical minoxidil. They credit their progress to dutasteride and support from Haircafe, a YouTuber.

HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.

User's 2-month hair loss treatment includes Dut 0.5mg, oral min 2.5mg, Dut+PRP mesotherapy, microneedling, and other products. Dermatologist increased min dose to 5mg, expecting better results at 6-month mark.

The conversation is about using GHK-Cu, a copper peptide, for hair loss treatment. Users discuss their experiences, dosages, and additional benefits like improved skin and energy.

User shows temple area progress after hair transplant, using DUT every other day and oral Min 2.5 daily. Another user asks about number of grafts and cost.

Finasteride helps with hair loss by lowering DHT levels in the scalp, which is more important than blood DHT levels. If finasteride is not effective, consulting a doctor or considering switching to dutasteride may be advisable.